Brent crude futures fell $1.36, or 1.55%, to $86.48 a barrel, while West Texas Intermediate (WTI) crude futures declined $1.40, or 1.7%, to $80.83 as markets reacted to expectations of reduced supply disruptions.
Standard Nuclear (NYSE:STDN) reported second quarter 2026 revenue of $4.7 million, up from $0.6 million in the prior-year period, while total contract backlog later increased to $576.9 million following new customer agreements.
Marvell Technology (NASDAQ:MRVL) reported record fiscal 2027 second-quarter net revenue of $2.739 billion, up 37% year over year and $39 million above the midpoint of its previous guidance.
Mesoblast (NASDAQ:MESO) reported FY2026 total revenue of $120.3 million, up from $17.2 million a year earlier, as the company recorded its first full U.S. commercial year of Ryoncil sales.
Materialise NV (NASDAQ:MTLS) reported second quarter 2026 revenue of EUR70.1 million, up 8.1% year over year, while adjusted EBITDA increased to EUR9.6 million from EUR8.3 million.
CMB.TECH (NYSE:CMBT) reported unaudited second quarter 2026 revenue of USD703.9 million, compared with USD387.8 million in the same period last year, while profit for the period reached USD364.4 million.
AbbVie (NYSE:ABBV) submitted a regulatory application to the European Medicines Agency for subcutaneous SKYRIZI (risankizumab) induction treatment in adults with moderately to severely active Crohn’s disease.
Aave (CRYPTO:AAVE) opened early access to its iOS savings app, while Android and web users remain waitlisted.
Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) reported positive Phase 3 results from the CROSSING trial of TEZSPIRE (tezepelumab-ekko), with the study meeting both primary endpoints in 368 patients with symptomatic eosinophilic esophagitis.
Official Trump (CRYPTO:TRUMP) rose nearly 90% in five days before giving back some gains.
GET YOUR GRAFA EDGE NOW
Sign up free to unlock this feature
We'll switch on a 30-day Edge trial as a welcome gift
